Implant Sciences' CEO Glenn Bolduc to Speak at the White House on U.S. Exports Bolduc to present at U.S. Department of Commerce's Advocacy Center roundtable discussion
WILMINGTON, Mass., Feb. 20, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced the Company's President & CEO, Glenn Bolduc has been invited by the United States Department of Commerce's International Trade Administration Advocacy Center to participate in a roundtable discussion at the White House on Friday February 21, 2014. The purpose of the meeting is to discuss how the Advocacy Center can best assist American companies in their efforts to export. Mr. Bolduc has been asked to make a brief presentation on Implant Sciences and how its export initiatives have been supported by the Advocacy Center.
"We are honored to be invited to make this presentation at the White House. Implant Sciences has benefitted from the U.S. Department of Commerce's Advocacy Center. We can directly attribute millions of dollars in sales that have resulted from Advocacy Center introductions and support," Bolduc stated. "As the only U.S.-owned and operated manufacturer of explosives trace detection equipment to have product approval from the TSA, we are proud to contribute to America's exports and to create high-tech jobs in the U.S."
Implant Sciences has an expanding global presence and has sold over 2,000 explosives trace detectors in more than 50 countries. The U.S. Department of Commerce's Advocacy Center has helped support Implant Sciences' sales efforts in many locations and was critical in completing the Company's $6 million contract with the Indian government in 2012. With 75 employees, Implant Sciences' ETDs are 100% manufactured in the USA.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at http://www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation